Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
July 01, 2025 09:00 ET | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase…
Visory Health Wins Gold at the 2025 Digital Health Awards
ESTERO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Visory Health, a leading…
Acceleware Announces Non-Brokered Private Placement of Units and Shares for Debt Transactions
CALGARY, Alberta, June 30, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or…
Acesis Biomed Secures Patents Advancing Testosterone-Inducing Drug Development
Centennial, Colorado, June 30, 2025 (GLOBE NEWSWIRE) -- Acesis Holdings Corporation (“Acesis Biomed”),…
Shoals Technologies Group, Inc. Announces Battery Energy Storage Systems (BESS) Webinar
PORTLAND, Tenn., June 30, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc.…
Transactions under Novonesis share buyback program
Novonesis has now completed the announced share buyback program of B shares…
OSE Immunotherapeutics Publishes Letter to Shareholders
OSE Immunotherapeutics Publishes Letter to Shareholders NANTES, France, June 30, 2025, 6:00…
Ripple Ends SEC LawsuitSunnyMining Cloud Mining Launches XRP Daily Cryptocurrency Earnings
New York City, June 29, 2025 (GLOBE NEWSWIRE) -- Ripple reached a…
BAY Miner Expands Cloud Mining Services for BTC, SOL, XRP, and DOGE
Boston, MA, June 29, 2025 (GLOBE NEWSWIRE) -- As Bitcoin (BTC) stabilizes…
